Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | MDM4 | O15151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2815583 | 0.79 | ALDH1A1 (0.45) | ALDH1A1KDM4EUSP2MAPTGAA | |
| SCHEMBL1684402 | 0.78 | MAPT (0.39) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| SCHEMBL30901480 | 0.78 | MAPT (0.39) | ALDH1A1KDM4EMAPTGAAMEN1 | |
| SCHEMBL1345421 | 0.78 | SLC6A2 (0.30) | — | |
| SCHEMBL2819804 | 0.78 | CYP3A4 (0.44) | ALDH1A1KDM4EUSP2MAPTGAA | |
| SCHEMBL2816728 | 0.78 | KDM4E (0.49) | ALDH1A1KDM4EUSP2MAPTGAA | |
| SCHEMBL2814720 | 0.78 | KIF11 (0.41) | ALDH1A1KDM4EUSP2GAAGLA | |
| SCHEMBL2814890 | 0.76 | GAA (0.50) | ALDH1A1KDM4EUSP2GAAMEN1 | |
| SCHEMBL22165426 | 0.76 | ALDH1A1 (0.45) | ALDH1A1KDM4EUSP2MAPTGAA | |
| SCHEMBL2814705 | 0.75 | ALDH1A1 (0.36) | ALDH1A1KDM4EUSP2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2010-09-30 | — | — | US | disclosed |
| CN-101679215-A | New benzamide derivatives as the follicle stimulating hormone conditioning agent | ADDEX PHARMA SA | 2010-03-24 | — | — | CN | disclosed |
| EP-2134676-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | Addex Pharma SA (CH) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008117175-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249123-A1 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | FSHR, GNRHR, SHBG | ALDH1A1 1769/4885KDM4E 1395/4885USP2 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.